GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Praxis Precision Medicines Inc (NAS:PRAX) » Definitions » ROC (Joel Greenblatt) %

Praxis Precision Medicines (Praxis Precision Medicines) ROC (Joel Greenblatt) % : -3,948.31% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Praxis Precision Medicines ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Praxis Precision Medicines's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -3,948.31%.

The historical rank and industry rank for Praxis Precision Medicines's ROC (Joel Greenblatt) % or its related term are showing as below:

PRAX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -25509.71   Med: -5027.38   Max: -3870.77
Current: -3870.77

During the past 6 years, Praxis Precision Medicines's highest ROC (Joel Greenblatt) % was -3870.77%. The lowest was -25509.71%. And the median was -5027.38%.

PRAX's ROC (Joel Greenblatt) % is ranked worse than
83.59% of 1469 companies
in the Biotechnology industry
Industry Median: -336.59 vs PRAX: -3870.77

Praxis Precision Medicines's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 22.40% per year.


Praxis Precision Medicines ROC (Joel Greenblatt) % Historical Data

The historical data trend for Praxis Precision Medicines's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Praxis Precision Medicines ROC (Joel Greenblatt) % Chart

Praxis Precision Medicines Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial -4,258.06 -5,134.05 -5,869.24 -4,920.71 -3,874.10

Praxis Precision Medicines Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4,121.60 -4,097.46 -4,102.08 -3,273.91 -3,948.31

Competitive Comparison of Praxis Precision Medicines's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Praxis Precision Medicines's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Praxis Precision Medicines's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Praxis Precision Medicines's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Praxis Precision Medicines's ROC (Joel Greenblatt) % falls into.



Praxis Precision Medicines ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 2.242) - (14.145 + 1.552 + 0)
=-13.455

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 3.58) - (13.231 + 1.392 + 1.7763568394003E-15)
=-11.043

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Praxis Precision Medicines for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-111.224/( ( (2.982 + max(-13.455, 0)) + (2.652 + max(-11.043, 0)) )/ 2 )
=-111.224/( ( 2.982 + 2.652 )/ 2 )
=-111.224/2.817
=-3,948.31 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Praxis Precision Medicines  (NAS:PRAX) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Praxis Precision Medicines ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Praxis Precision Medicines's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Praxis Precision Medicines (Praxis Precision Medicines) Business Description

Traded in Other Exchanges
N/A
Address
99 High Street, 30th Floor, Boston, MA, USA, 02110
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.
Executives
Jill Desimone director C/O PRAXIS PRECISION MEDICINES, INC., 99 HIGH STREET, 30TH FLOOR, BOSTON MA 02110
Marcio Souza officer: Chief Executive Officer C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Dean J Mitchell director C/O BRISTOL MYERS SQUIBB CO, 345 PARK AVE, NEW YORK NY 10164
Timothy Edwin Kelly officer: Chief Financial Officer C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Lauren Mastrocola officer: Principal Accounting Officer C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Alex Nemiroff officer: General Counsel and Secretary C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Bsof Parallel Master Fund L.p. 10 percent owner 345 PARK AVENUE, NEW YORK NY 10154
Merit Ester Cudkowicz director C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Jeffrey Chodakewitz director C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL ST., SUITE 101, WATERTOWN MA 02472
Stefan Vitorovic director C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Blackstone Holdings I/ii Gp L.l.c. 10 percent owner C/O BLACKSTONE INC., 345 PARK AVENUE, NEW YORK NY 10154
William D Young director 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Stephen A Schwarzman 10 percent owner C/O BLACKSTONE INC., 345 PARK AVE, NEW YORK NY 10154
Blackstone Inc. 10 percent owner 345 PARK AVENUE, NEW YORK NY 10154
Blackstone Group Management L.l.c. 10 percent owner C/O BLACKSTONE INC., 345 PARK AVENUE, NEW YORK NY 10154

Praxis Precision Medicines (Praxis Precision Medicines) Headlines